Cell Line Development Market Size

Cell Line Development Market size was over USD 5.44 billion in 2023 and is poised to cross USD 19 billion by 2036, witnessing more than 10.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of cell line development is evaluated at USD 5.88 billion. Further, the market generated a revenue of USD 4,588.5 Million in the year 2021. The growth of the market can be attributed to the growing demand for monoclonal antibodies. These antibodies help to stimulate immune system. Thus they are extensively used for treating cancer, migraines, and more. Further, rising burden of cancer is expected to boost the market growth. According to the World Health Organization, Cancer is the most common cause of death worldwide, accounting for almost 10 million fatalities in 2020, or nearly one in every six deaths.

Moreover, rising need for vaccine production is anticipated to fuel the growth of the cell line development market. The cell line development technology is used in manufacturing various vaccines in order to treat viral infection such as HIV, influenza, and more. These vaccines prove to stimulate body immune system. Besides this, cell line technology has successful manufactured vaccine which could treat mild or moderate coronavirus. For a novel monoclonal antibody to treat COVID-19 that prevents the activity of the omicron variant, the US Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) in February 2022.